Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pelthos Therapeutics Inc. (PTHS : AMEX)

• Company Description    Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $24.55 Daily Weekly Monthly 20 Day Moving Average: 42,850 shares Shares Outstanding: 3.83 (millions) Market Capitalization: $93.99 (millions) Beta: 3.01 52 Week High: $37.50 52 Week Low: $18.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.25% -13.64% 12 Week -12.38% -14.24% Year To Date -20.81% -29.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4020 STIRRUP CREEK DRIVE SUITE 110 - DURHAM,NC 27703 USA ph: 919-908-2400 fax: - mmoyer@lifesciadvisors.com http://www.pelthos.com

• General Corporate Information    Officers Scott Plesha - Chief Executive Officer and President Peter Greenleaf - Chairman Francis Knuettel - Chief Financial Officer Andrew Einhorn - Director Todd Davis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171126204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 3.83 Most Recent Split Date: 7.00 (0.10:1) Beta: 3.01 Market Capitalization: $93.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-15.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.17 EPS Growth vs. Year Ago Period: -23.05% vs. Previous Quarter: -114.24% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 43.07% ROE 06/30/26 - -204.71 03/31/26 - -141.34 12/31/25 - -141.43 ROA 06/30/26 - -43.59 03/31/26 - -38.54 12/31/25 - -47.28 Current Ratio 06/30/26 - 1.98 03/31/26 - 2.79 12/31/25 - 2.05 Quick Ratio 06/30/26 - 1.31 03/31/26 - 1.86 12/31/25 - 1.15 Operating Margin 06/30/26 - -135.79 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - -165.24 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - -216.56 03/31/26 - -266.46 12/31/25 - -301.91 Book Value 06/30/26 - -0.43 03/31/26 - 5.74 12/31/25 - 12.02 Inventory Turnover 06/30/26 - 0.40 03/31/26 - 0.32 12/31/25 - 0.33 Debt-to-Equity 06/30/26 - - 03/31/26 - 3.40 12/31/25 - 0.81 Debt-to-Capital 06/30/26 - - 03/31/26 - 77.26 12/31/25 - 44.71

Powered by Zacks Investment Research ©